oxbryta
pfizer europe ma eeig - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
venclyxto (▼) 10 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 10 mg/1 tableta - 1 filmom obložena tableta sadrži: 10 mg venetoklaksa
venclyxto (▼) 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg venetoklaksa
venclyxto (▼) 100 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 100 mg/1 tableta - 1 filmom obložena tableta sadrži: 100 mg venetoklaksa
venclyxto (▼) 50 mg/1 tableta filmom obložena tableta
abbvie d.o.o. - venetoklaks - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg venetoklaksa
xtandi
astellas pharma europe b.v. - enzalutamide - prostatske neoplazme - endokrinska terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
litfulo
pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresivi - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.
metoject 50 mg/ml otopina za injekciju u napunjenoj štrcaljki
medac gesellschaft für klinische spezialpräparate mbh, theaterstraße 6, wedel, njemačka - dinatrijev metotreksat - otopina za injekciju u napunjenoj štrcaljki - 50 mg/ml - urbroj: 1 ml otopine sadrži 50 mg metotreksata (u obliku dinatrijevog metotreksata)
namaxir 10 mg otopina za injekciju u napunjenoj štrcaljki
teva b.v., swensweg 5, haarlem, nizozemska - metotreksat - otopina za injekciju u napunjenoj štrcaljki - 10 mg - urbroj: jedna napunjena štrcaljka od 0,40 ml sadrži 10 mg metotreksata
namaxir 12,5 mg otopina za injekciju u napunjenoj štrcaljki
teva b.v., swensweg 5, haarlem, nizozemska - metotreksat - otopina za injekciju u napunjenoj štrcaljki - 12,5 mg - urbroj: jedna napunjena štrcaljka od 0,31 ml sadrži 12,5 mg metotreksata